Revance / Crown Laboratories

Revance Therapeutics, Inc. is the company that developed Daxxify, a U.S.-approved botulinum toxin type A product with the nonproprietary name daxibotulinumtoxinA-lanm. Crown Laboratories completed its acquisition of Revance in February 2025, so the Revance name now carries both the product-development history and the current Crown Laboratories ownership context.

This distinction matters because “Revance,” “Revance Therapeutics Inc.,” and “Crown Laboratories Revance” can all appear in searches for the same corporate story. Revance remains important to Daxxify’s development, clinical, regulatory, and commercialization record, while Crown supplies the current private-company context after the acquisition.

Reference Card

Field	Reference point
Company names readers may encounter	Revance; Revance Therapeutics, Inc.; Crown Laboratories; Crown Laboratories / Revance
Current company context	Revance within the Crown Laboratories corporate group
Base	United States
Current headquarters context	Revance’s official site lists Nashville, Tennessee; Crown’s corporate history also points to Johnson City, Tennessee as Crown’s headquarters base
Website	revance.com 🔗 and crownlaboratories.com 🔗
Ownership status	Privately held following Crown Laboratories’ February 2025 acquisition of Revance
Core toxin relationship	Development and commercialization context for Daxxify
Main brand node	Daxxify
Product identity	DaxibotulinumtoxinA-lanm, botulinum toxin type A

What Happened to Revance?

Revance did not disappear as a product-development reference after the Crown transaction. Crown completed the acquisition through a tender offer and second-step merger in February 2025, after which Revance’s former Nasdaq-listed shares were delisted and deregistered. That changed the ownership and public-company status, not the product’s regulatory identity.

For Daxxify, the most useful reading is therefore split:

Question	Short answer
Who developed Daxxify?	Revance Therapeutics developed daxibotulinumtoxinA-lanm and built the product’s clinical and regulatory record.
Who owns the current Revance business context?	Crown Laboratories acquired Revance in 2025 and now provides the broader corporate context.
Is Revance still public?	No. Revance became part of a privately held Crown Laboratories group after the acquisition.
Did the acquisition make a new toxin product?	No. Daxxify remains daxibotulinumtoxinA-lanm, interpreted through its own label and evidence.

Development and Ownership Timeline

Revance developed Daxxify Revance developed daxibotulinumtoxinA-lanm and built the product’s clinical, regulatory, manufacturing, and commercialization history.
Daxxify received its first U.S. approval in 2022 Current U.S. prescribing information includes aesthetic use for glabellar lines and therapeutic use for cervical dystonia in adults. Each indication remains governed by the product-specific label.
Crown acquired Revance in February 2025 Crown completed the acquisition after its tender offer and second-step merger. Revance’s former Nasdaq-listed shares were delisted, and Daxxify became part of the combined private-company portfolio.

Locations and Company Identity

Current official Revance materials identify the company with a Nashville, Tennessee headquarters address. Crown’s own company history describes Crown Laboratories as founded in 2000 and its corporate headquarters opening in Johnson City, Tennessee in 2019, before the 2025 acquisition of Revance.

Searches such as “Revance Reston” or “Revance Clermont” are best treated as location-confirmation queries unless a current official company source ties those places to a specific Revance facility, office, or business unit. They should not override the current company identity: Revance is now a Crown Laboratories company context, and Daxxify remains the relevant botulinum toxin product node.

Product and Formulation Context

Revance describes Daxxify as a peptide-formulated botulinum toxin product. That formulation identity is a sourced product distinction, but it should not be converted into a general claim that Daxxify is safer, stronger, longer-lasting, or clinically superior across patients or uses.

Daxxify potency units are product-specific. The product’s corporate history and formulation do not create a conversion relationship with Botox, Dysport, Xeomin, Jeuveau, Letybo, or another botulinum toxin product.

Person	Why the relationship matters
Mark Foley	Historical Revance CEO node for the period around Daxxify’s original FDA approval and early commercialization.
Nadeem Moiz	Current Revance CEO after Crown’s acquisition, useful for separating post-2025 company structure from Revance Therapeutics’ public-company history.
Steve Kreider	Current Revance revenue leader for aesthetics and therapeutics, useful for Daxxify commercialization context after the Crown acquisition.
Thomas Hitchcock, Ph.D.	Current Revance innovation leader, connecting Daxxify’s peptide-formulated product identity to product-science context without turning it into a superiority claim.
Conor Gallagher, Ph.D.	Current Revance Chief Scientific Officer, useful for separating science leadership from promotional formulation or duration claims around Daxxify.
Jeff Bedard	Crown / Revance transition leader, useful for explaining the 2025 acquisition and name-transition period without treating it as Daxxify product-development history.
Nick Crowe	Current Revance Chief Operating Officer, useful for post-acquisition operations, supply-chain, production, and quality context around the combined portfolio.

Market Interpretation

The Revance / Crown node preserves continuity across an ownership change. Keeping both names on one page avoids treating the acquisition as if it erased the product’s development history, created a new regulatory identity, or made Revance a separate public-company investment reference after the 2025 delisting.

Daxxify is the reason this company page belongs in the botulinum toxin manufacturer graph. Crown’s broader portfolio also includes aesthetics, skincare, and device-related businesses, but those adjacent lines should not blur the core toxin relationship: Revance developed Daxxify, and Daxxify’s label, units, indications, and safety language remain product-specific.